{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:56:39Z","timestamp":1793656599018,"version":"4.5.1"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This meta-analysis systematically evaluated the efficacy and safety of B-cell maturation antigen (BCMA)\u2013directed chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory multiple myeloma (RRMM) with extramedullary disease (EMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, Web of Science, and the Cochrane Library were searched for studies published up to December 2024 reporting CAR T-cell therapy in RRMM patients with EMD. Studies were screened according to predefined inclusion and exclusion criteria. Data were extracted and the methodological quality was assessed using the Newcastle\u2013Ottawa Scale (NOS) and the MINORS tool; one low-quality study was excluded. A total of 42 studies were included, comprising 242 RRMM patients with EMD and 1,485 without EMD. Fixed- or random-effects models were applied to pool effect sizes. Primary outcomes included objective response rate (ORR), complete response (CR), progression-free survival (PFS), and overall survival (OS). Secondary outcomes included cytokine release syndrome (CRS) and immune effector cell\u2013associated neurotoxicity syndrome (ICANS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The pooled ORR and CR rates were 79% (95%CI: 71%\u201386%) and 42% (95%CI: 32%\u201351%) in the EMD group, and 90% (95%CI: 86%\u201393%) and 49% (95%CI: 40%\u201358%) in the non-EMD group, respectively. Reported median PFS ranged from 3 to 18.8 months in the EMD grouPand from 1 to 38 months in the non-EMD group, while median OS ranged from 6 to 13.9 months and from 12.2 to 38 months, respectively. The pooled incidences of grade \u22653 CRS and ICANS were 18% (95%CI: 8%\u201327%) and 5% (95%CI: 3%\u20137%) in the EMD group, compared with 13% (95%CI: 7%\u201319%) and 6% (95%CI: 2%\u20139%) in the non-EMD group; none of the differences were statistically significant (P&amp;gt; 0.05). Due to inconsistent reporting and lack of individual patient-level data, hazard ratios and pooled time-to-event analyses were not feasible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although RRMM patients with EMD exhibited lower ORR and CR rates than those without EMD, BCMA-directed CAR T therapy demonstrated notable clinical activity with a manageable safety profile. However, no direct comparisons with conventional therapies were performed in this analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42025613422<\/jats:ext-link>\n                      , identifier CRD42025613422.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1792558","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:47:14Z","timestamp":1776836834000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of BCMA-directed CAR T-cell therapy in extramedullary relapsed or refractory multiple myeloma: a meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yan-ling","family":"Li","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"Department of Hematology, Chinese People\u2019s Liberation Army The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-jiao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"Department of Hematology, Chinese People\u2019s Liberation Army The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-jia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"Department of Hematology, Chinese People\u2019s Liberation Army The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chinese People\u2019s Liberation Army The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-yang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chinese People\u2019s Liberation Army The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]},{"name":"Institute of Basic Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chinese People\u2019s Liberation Army The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chinese People\u2019s Liberation Army The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-chun","family":"Fan","sequence":"additional","affiliation":[{"name":"Institute of Oncology, The First Affiliated Hospital of Hebei North University","place":["Zhangjiakou, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-hui","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chinese People\u2019s Liberation Army The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chinese People\u2019s Liberation Army The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]},{"name":"Institute of Basic Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"College of Medicine, Southwest Jiaotong University","place":["Chengdu, Sichuan, China"]},{"name":"Reproductive Medicine Center, Chinese People\u2019s Liberation Army The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]},{"name":"Tissue Stress Injury and Functional Repair Key Laboratory of Sichuan Province","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-yi","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"Department of Hematology, Chinese People\u2019s Liberation Army The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma","volume":"327","author":"Cowan","year":"2022","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-007-9108-4","article-title":"Extravasation and homing mechanisms in multiple myeloma","volume":"25","author":"Vande Broek","year":"2007","journal-title":"Clin Exp Metastasis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-791228","article-title":"Ixazomib significantly prolongs progression-free survival in high-risk relapsed\/refractory myeloma patients","volume":"130","author":"Avet-Loiseau","year":"2017","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755866","article-title":"Anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma patients with extramedullary disease: a single center analysis of two clinical trials","volume":"12","author":"Que","year":"2021","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani","year":"2019","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1038\/s41467-025-56486-6","article-title":"Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma","volume":"16","author":"Hosoya","year":"2025","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Blad\u00e9","year":"2011","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13045-022-01374-5","article-title":"Phase II trial of daratumumab with DCEP in relapsed\/refractory multiple myeloma patients with extramedullary disease","volume":"15","author":"Byun","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.275","article-title":"Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed\/refractory multiple myeloma with extramedullary disease","volume":"2","author":"Abdallah","year":"2021","journal-title":"eJHaem"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.178434","article-title":"Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT","volume":"103","author":"Gagelmann","year":"2018","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.12354\/j.issn.1000-8179.2024.20240398","article-title":"Long-term efficacy and factors influencing BCMA chimeric antigen receptor-T cell treatment in relapsed or refractory multiple myeloma","volume":"51","author":"Yu","year":"2024","journal-title":"Chin J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-021-2373-7","article-title":"Anti-BCMA CAR T-cell therapy in relapsed or refractory multiple myeloma patients with impaired renal function","volume":"41","author":"He","year":"2021","journal-title":"Curr Med Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755866","article-title":"Anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma patients with extramedullary disease: a single center analysis of two clinical trials","volume":"12","author":"Que","year":"2021","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/blood-2021-148375","article-title":"Baseline correlates of complete response to idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in patients with relapsed and refractory multiple myeloma: subanalysis of the KarMMa trial","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02129-y","article-title":"Cellular dynamics following CAR T-cell therapy are associated with response and toxicity in relapsed\/refractory myeloma","volume":"38","author":"Fischer","year":"2024","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15556","article-title":"Ciltacabtagene autoleucel in patients with relapsed\/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort","volume":"113","author":"Ri","year":"2022","journal-title":"Cancer Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8005","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR T) therapy, in relapsed\/refractory multiple myeloma (R\/R MM): updated results from CARTITUDE-1","volume":"39","author":"Usmani","year":"2021","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-160401","article-title":"Clinical outcomes and salvage therapies in patients with relapsed\/refractory multiple myeloma following progression on BCMA-targeted CAR T therapy","volume":"140","author":"Reyes","year":"2022","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2018-99-119717","article-title":"Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T-cell therapy in relapsed\/refractory multiple myeloma: final results of a phase I clinical trial","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133471","article-title":"Clonal myeloid dysplasia following CAR T-cell therapy: chicken or the egg","volume":"15","author":"Vainstein","year":"2023","journal-title":"Cancers"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.10.013","article-title":"Comparison of Cilta-cel, an anti-BCMA CAR T-cell therapy, versus conventional treatment in patients with relapsed\/refractory multiple myeloma","volume":"22","author":"Costa","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01226-9","article-title":"CRS-related coagulopathy in BCMA targeted CAR T therapy: a retrospective analysis in a phase I\/II clinical trial","volume":"56","author":"Shao","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138839","article-title":"Deep and durable remissions of relapsed multiple myeloma on a first-in-humans clinical trial of T cells expressing an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) with a fully-human heavy-chain-only antigen recognition domain","volume":"136","author":"Mikkilineni","year":"2020","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.740.740","article-title":"Durable clinical responses in heavily pretreated patients with relapsed\/refractory multiple myeloma: updated results from a multicenter study of bb2121 anti-BCMA CAR T-cell therapy","volume":"130","author":"Berdeja","year":"2017","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.03.004","article-title":"Early time-to-tocilizumab after B cell maturation antigen-directed chimeric antigen receptor T cell therapy in myeloma","volume":"27","author":"Banerjee","year":"2021","journal-title":"Elsevier"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2958","article-title":"Efficacy and follow-up of humanized anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease","volume":"40","author":"Li","year":"2022","journal-title":"Hematol Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1182\/blood-2019-129405","article-title":"Efficacy and safety of fully human BCMA CAR T-cells in combination with a gamma secretase inhibitor to increase BCMA surface expression in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Cowan","year":"2019","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.720571","article-title":"Efficacy of humanized anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma patients with and without extramedullary disease","volume":"12","author":"Deng","year":"2021","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Thiruvengadam","year":"2022","journal-title":"Blood Adv"},{"key":"B34","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1182\/blood-2018-99-116953","article-title":"Initial results from a phase 1 clinical study of bb21217, a next-generation anti BCMA CAR T therapy","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood-2019-124953","article-title":"Long-term follow-up of a phase 1, first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280629","article-title":"A novel BCMA CAR T-cell therapy with optimized human scFv for treatment of relapsed\/refractory multiple myeloma: results from phase I clinical trials","volume":"107","author":"Yang","year":"2022","journal-title":"Haematologica"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1182\/blood-2023-181331","article-title":"Outcomes of BCMA-directed chimeric antigen receptor T-cell (CART) therapy in patients with relapse-refractory multiple myeloma with extramedullary disease","volume":"142","author":"Dima","year":"2023","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008429","article-title":"PD-1 downregulation enhances CAR T-cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion","volume":"12","author":"Ouyang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.36.15_suppl.tps3103","article-title":"A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed\/refractory multiple myeloma","volume":"11","author":"Cornell","year":"2021","journal-title":"Am J Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00690","article-title":"Phase II, open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1)","volume":"41","author":"Mi","year":"2023","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1182\/blood-2019-121731","article-title":"Results from CARTITUDE-1: a phase 1b\/2 study of JNJ-4528, a CART cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and\/or refractory multiple myeloma (R\/R MM)","volume":"134","author":"Berdeja","year":"2019","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-160038","article-title":"Results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) Nex T chimeric antigen receptor (CAR) T cell therapy CC-98633\/BMS-986354 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"140","author":"Mailankody","year":"2022","journal-title":"Blood"},{"key":"B43","article-title":"Safety and efficacy of a locally produced novel anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory multiple myeloma","author":"Lebel","year":"2023"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-190413","article-title":"Sequential administration of selinexor and CAR T therapy in relapsed\/ refractory multiple myeloma","volume":"142","author":"Gill","year":"2023","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1182\/blood-2019-129088","article-title":"T cells expressing an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor with a fully-human heavy-chain-only antigen recognition domain induce remissions in patients with relapsed multiple myeloma","volume":"134","author":"Cohen","year":"2019","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1182\/blood-2020-140156","article-title":"Two-year follow-up of investigator-initiated phase 1 trials of the safety and efficacy of fully human anti-BCMA CAR T-cells (CT053) in relapsed\/refractory multiple myeloma","volume":"136","author":"Hao","year":"2020","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146518","article-title":"Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR T-cell therapy bb21217 in patients with relapsed and refractory multiple myeloma","volume":"138","author":"Raje","year":"2021","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1182\/blood-2019-130008","article-title":"Updated phase 1 results of a first-in-human open-label study of Lcar-B38M, a structurally differentiated chimeric antigen receptor T (CAR T) cell therapy targeting B-cell maturation antigen (Bcma)","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood-2019-126660","article-title":"Updated results from an ongoing phase 1 clinical study of bb21217 anti-Bcma CAR T-cell therapy","volume":"134","author":"Berdeja","year":"2019","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146060","article-title":"Updated results from CARTITUDE-1: Phase 1b\/2study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Martin","year":"2021","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood-2020-140410","article-title":"Updated results from the phase I CRB-402 study of anti-Bcma CAR T-cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: Correlation of expansion and duration of response with T cell phenotypes","volume":"136","author":"Alsina","year":"2020","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41408-024-01068-w","article-title":"Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy","volume":"14","author":"Dima","year":"2024","journal-title":"Blood Cancer J"},{"key":"B54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/CJI.0000000000000391","article-title":"BCMA CAR T therapy is safe and effective for refractory\/relapsed multiple myeloma with central nervous system involvement","volume":"45","author":"Wang","year":"2022","journal-title":"J Immunother"},{"key":"B55","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2020-140243","article-title":"Chimeric antigen receptor T cell therapy in the relapsed or refractory multiple myeloma with extramedullary disease--a single institution observation in China","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27469","article-title":"Clinical outcomes and microenvironment profiling in relapsed\/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy","volume":"99","author":"Qi","year":"2024","journal-title":"Am J Hematol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.46811","article-title":"Efficacy and safety of CAR T therapy for relapse or refractory multiple myeloma: a systematic review and meta-analysis","volume":"18","author":"Yang","year":"2021","journal-title":"Int J Med Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1792558\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T09:55:19Z","timestamp":1776938119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1792558\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2026.1792558"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1792558","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1792558"}}